The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Best Lupus Treatment Still Up for Debate

Best Lupus Treatment Still Up for Debate

December 1, 2009 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

PHILADELPHIA—At the ACR/ARHP Annual Scientific Meeting in Philadelphia, three researchers continued the ongoing debate about optimal treatment strategies of lupus nephritis. As the debate indicated, lack of solid data on certain populations, concerns about side effects, and insufficient follow-up preclude consensus until more research has been completed.

You Might Also Like
  • Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Immunosuppressive Treatment for Lupus in the Next Decade
Explore This Issue
December 2009

For induction therapy, the choices are generally highdose IV cyclophosphamide (CY), the so-called National Institutes of Health (NIH) regimen; low-dose IV CY, the socalled Euro-Lupus regimen;1 azathioprine (AZ); or mycophenolate mofetil (MMF). There has also been recent use of the biologic rituximab. All of these immunosuppressive agents are used in combination with glucocorticoids.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For maintenance therapy, also the subject of continuing debate, the choices are often high-dose CY; low-dose CY; AZ and the Euro-Lupus regime; MMF; rituximab/CY combination; or rituximab alone.

Much of the debate centers on the efficacy of CY versus MMF. Although the NIH regime has improved survival and remission rates, not all patients have a favorable response, and toxicities are not uncommon with the high-dose regimen. These toxicities can include ovarian failure, severe infections, and reduced efficacy in black patients. Complicating the decision making at this point is the lack of long-term data for other therapies, as well as trials that do not indicate superiority of one drug over another.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

According to Ellen M. Ginzler, MD, MPH, chief of rheumatology at State University of New York-Downstate Medical Center in Brooklyn, there is an “unmet need for new agents.” But until those agents are developed, “if we can show equal efficacy, then we need to consider the tolerability and compliance issues, the racial and ethnic issues, the cost, availability, and reimbursement for these agents,” she said.2

Frederic A. Houssiau, MD, PhD, of the department of rheumatology at Universite Catholique Louvain in Brussels, Belgium, said that further drug development is needed for better maintenance therapy. “We don’t have a good maintenance therapy so far,” he said, adding that what a physician does at the bedside remains most important, including good follow-up; controlling blood pressure, blood sugar, and proteinuria with either angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers; and treating dyslipidemia. To illustrate the factors that complicate treatment strategies, the panel considered three high-risk cases.

Case 1: Young Black Woman

The first case was that of a 34-year-old black woman with new-onset class IV lupus nephritis and moderate renal function. She has one child and does not want another. After treatment for six months, she had complete renal remission. The two questions related to her case centered on the best induction therapy and best maintenance therapy.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: azathioprine, cyclophosphamide, Glucocorticoids, Lupus nephritis, mycophenolate mofetil, prednisone, rituximabIssue: December 2009

You Might Also Like:
  • Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Immunosuppressive Treatment for Lupus in the Next Decade
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)